CHF-6333

CHF-6333 is an investigational small molecule drug developed as a 24-hour durable dry powder inhaler (DPI) formulation for the treatment of respiratory diseases such as non-cystic fibrosis bronchiectasis and cystic fibrosis. Its mechanism of action is based on the inhibition of human neutrophil elastase (also known as leucocyte elastase), which plays a key role in inflammation and tissue damage in these conditions. The drug is classified as a new chemical entity and has received orphan drug designation for cystic fibrosis. It is currently in Phase II clinical development for bronchiectasis[1][4][6].

Other names

(R)-2-(5-Cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-(1,2,4)triazolo(4,3-a)pyrimidin-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate